The transdermal delivery system is a patent-pending invention and therefore the term "non-exclusive" does not apply. Otiko has no ownership in this invention.
The two named inventors of the delivery system have stated different intentions. Keough has stated their intention to protect it. Phillips has stated no intent to pursue a Grant for it.
What Otiko has announced is a non-exclusive agreement with Phillips, a named inventor of the above referenced published patent application. The agreement is for Diabecline clone Viabecline. This tetracycline topical is an approved use of the patent-pending delivery system.
If this technology is non-exclusive, it can't be patented or doesn't need a protection.
News 
Market Data 
Discover 
